



CODEN [USA]: IAJPBB

ISSN : 2349-7750

INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

SJIF Impact Factor: 7.187

<https://doi.org/10.5281/zenodo.7070638>

Available online at: <http://www.iajps.com>

Research Article

COMPARATIVE OUTCOMES OF MACE AFTER DRUG ELUTING BALLOON VS. DRUG ELUTING STENT IN TREATMENT OF IN-STENT RESTENOSIS (ISR) PATIENTS PRESENTED WITH ACUTE CORONARY SYNDROME

Shahsawar¹, Khalid², Mahmood ul Hassan³, Muhammad Idrees Khan⁴, Adnan Khan⁵

¹Consultant Interventional Cardiologist, Hayatabad Medical Complex, Peshawar.

²Resident Cardiologist, Hayatabad Medical Complex, Peshawar.

³Consultant Interventional Cardiologist, Hayatabad Medical Complex, Peshawar.

⁴Resident Cardiologist, Hayatabad Medical Complex, Peshawar.

⁵Registrar Cardiology Department, Hayatabad Medical Complex, Peshawar.

Article Received: July 2022

Accepted: August 2022

Published: September 2022

Abstract:

Introduction: Currently, coronary stenting has been recommended as a primary strategy of revascularization for patients with coronary artery disease.

Objective: To compare outcome of MACE after DEB Vs DES in treatment of patients with In stent restenosis (ISR) presented with chest pain

Methodology: The current study was Quasi experimental study carried out at the Department of Cardiology, MTI-HMC Peshawar for duration of six months from 21 April, 2021 to 21 Nov, 2021. In this study, 94 patients in DEB group and 94 patients in DES group were followed for 06 months to look for development of MACE. All data was collected through a well-defined proforma. Data was entered on computer software SPSS version 22.

Results: In DEB group, 52 (55.3%) male patients and 42 (44.7%) female patients were recorded whereas in DES group, 57 (60.6%) male patients while 37 (39.4%) female patients were recorded. In DEB group, 15 (16.0%) patients were recorded with MACE whereas in DES group, 38 (40.4%) patients were recorded with MACE.

Conclusion: Our study demonstrated that DEB is superior to DES in the in-stent restenosis treatment and a smaller number of major adverse cardiovascular events (MACE) in managing CAD, and therefore DEB may be considered as an alternative choice for treatment of CAD patients admitted in our setting in order to reduce mortality and morbidity associated with restenosis in such patients.

Key words: Coronary Artery Disease, Drug-Eluting Stents, Drug Eluting Balloon, Restenosis

Corresponding author:

Dr. Adnan Khan,

Registrar Cardiology,

Hayatabad Medical complex, Peshawar.

Email : dr.adnan34@gmail.com

QR code



Please cite this article in press Shahsawar et al, *Comparative Outcomes Of Mace After Drug Eluting Balloon vs. Drug Eluting Stent In Treatment Of In-Stent Restenosis (ISR) Patients Presented With Acute Coronary Syndrome.*, Indo Am. J. P. Sci, 2022; 09(9).

INTRODUCTION:

Presently, patients with coronary artery disease are advised to use coronary stenting as their main revascularization approach ¹. One of the problems with PCI (percutaneous coronary intervention) is ISR (in-stent restenosis). Despite the fact that drug-eluting stents (DES) have decreased the prevalence of ISR, it still affects 5%–10% of patients having PCI and is a serious issue ². One of the clinical problems that are yet unsolved and stubborn is restenosis. Patients with DES-ISR need more difficult treatment ³.

Drug eluting stents ISR is characterized by delayed vessel healing as a result of the stent materials, like the durable polymer, which generally manifests after two years as opposed to bare metal stent ISR, which normally takes between six and eight months to manifest. Vascular damage and the ensuing intima inflammation function as the first stimulus for multiplication and stimulation of vascular smooth muscle. As a result, myofibroblast move to create neointimal layer and extracellular matrix that is coated by endothelial cells above the stented section, leading to restenosis of the stent ⁴. Additionally, a previous study identified the stent under-expansion as a significant possible ISR mechanism ⁵.

Individuals diagnosed with recurrent ISR have been treated with a variety of therapeutic modalities, including drug eluting balloon (DEB) dilation, DES repeated implantation, brachytherapy and excimer laser angioplasty.

The best course of action for recurring DES-ISR is currently unknown. According to prediction, redeployment of new stents with multi-metallic layers would itself contribute to lumen loss at lesions, particularly in vessels with a small diameter ⁶. Recurrent DES-ISR patients managed with new generation DES repeat deployment had 30.8% and 24.2% 1-year rates of severe adverse cardiovascular events and ischemia-driven target lesion revascularization, respectively, according to a study by Varghese *et al.* ⁷. Drug-eluting balloon angioplasty is a novel approach to treating ISR. A unique therapy option for ISR is DEB, which does not require to employ supplementary layers of metal stents and may administer anti-proliferative drugs to a restenotic artery part ⁸.

Outcome of these treatment modalities is not widely known. In previous study MACE (major adverse cardiovascular event) was present in 32.9% patients treated with reimplanted DES and 17.2% patients treated with DEB ⁶.

The rationale of this study is to compare outcome of DEB and DES in patients of in-stent restenosis. Finding a long-term outcome helped us in determining the efficacy of treatment modality and reduced mortality and morbidity associated with restenosis.

MATERIALS AND METHODS:

The current study was Quasi experimental study carried out at the Department of Cardiology, MTI-HMC Peshawar for duration of six months from 21 April, 2021 to 21 Nov, 2021. Sample size was calculated using open epi software keeping 95% confidence level, 80% power of study, 32.9% MACE in DES group and 17.2% in DEB group ⁶. Sample size was n=188 patients, n₁=94 and n₂=94 patients in each group. Non-probability, consecutive sampling method was employed. The inclusion criteria of our study were patients of age between 17-60 years, patients of both gender, patients with previously done DEB and DES after In stent restenosis and patient on optimal medical therapy with compliance whereas criteria for exclusion were patient on optimal medical therapy with non-compliance and patients with coronary arterial bypass graft CABG.

After approval from hospital ethical committee, 188 patients fulfilling inclusion / exclusion criteria with the diagnosis of in-stent restenosis were enrolled from emergency department of HMC Peshawar. Written informed consent was taken. Demographic data regarding age, gender, residence, duration of symptoms, smoking (at least for last 6 months), diabetes (RBS more than 200mg/dl), hypertension (systolic BP more than 130mmHg at rest), hyperlipidemia (fasting serum cholesterol more than 200mg/dl) obesity (> 25Kg/m²) and family history of coronary disease was noted. Patients was admitted and treated for chest pain as per hospital protocol. 94 patients in DEB group and 94 patients in DES group were followed for 06 months to look for development of MACE. Patients developing MACE was managed as per hospital protocols. All data was collected through a well-defined proforma. Data was entered on computer software SPSS version 22. Quantitative data like age, and duration of symptoms was presented by mean and standard deviation for both groups. Qualitative data like gender, diabetes, hypertension, smoking, obesity, hyperlipidemia, family history and MACE was presented by frequency and percentages for both groups. Both groups were compared for presence of MACE by employing chi square test and p-value of ≤ 0.05 was considered significant statistically.

RESULTS:

This study was conducted on 188 patients (94 patients in each group) admitted at the Department of Cardiology, Hayatabad Medical Complex, Peshawar. In DEB group, the mean (\pm SD) age, duration of symptoms, BMI was 51.43 (\pm 5.104) years, 3.52 (\pm 1.233) months and 25.39 (\pm 0.88) kg/m² respectively while in DES group, the mean (\pm SD) age, duration of symptoms, BMI was 51.49 (\pm 5.299), 3.56 (\pm 1.205) and 25.364 (\pm 0.885) respectively. (Figure 1) Based on age distribution, in DEB group 21 (22.3%) patients were observed in age group < 50 years while 73 (77.7%) patients were observed in age group > 50 years whereas in DES group, 23 (24.5%) patients were observed in age group < 50 years whereas 71 (75.5%) patients were observed in age group > 50 years. In DEB group, 52 (55.3%) male patients and 42 (44.7%) female patients were recorded whereas in DES group, 57 (60.6%) male patients while 37 (39.4%) female patients were recorded. In DEB group, 35 (37.2%) patients were recorded with diabetes. In DES group, 27 (28.7%)

patients were recorded with diabetes in DES group. In DEB group, 33 (35.1%) patients were recorded with hypertension. In DES group, 25 (26.6%) patients were recorded with hypertension. In DEB group, 26 (27.7%) patients were recorded with smoking history whereas in DES group, 30 (31.9%) patients were recorded with smoking history. In DEB group, 39 (41.5%) patients were recorded with obesity while in DES group, 35 (37.2%) patients were recorded with obesity. In DEB group, 35 (37.2%) patients were recorded with hyperlipidemia while in DES group, 36 (38.3%) patients were recorded with DES group. In DEB group, 41 (43.6%) patients were recorded with family history of coronary disease. In DES group, 29 (30.9%) patients were recorded with family history of coronary disease. (Table 1) As per frequencies and percentages for MACE in both groups, in DEB group, 15 (16.0%) patients were recorded with MACE. In DES group, 38 (40.4%) patients were recorded with MACE. (Table 2)




Figure 1: Mean age, duration of symptoms and BMI in both the group (Drug Eluting Balloon (DEB) Drug-Eluting Stents (DES))

Table 1: Socio-demographic and clinical parameters of the enrolled patients

Parameter	Sub category	DEB group Mean (SD)	DES group Mean (SD)	P value
Gender	Male	52 (55.3%)	57(60.6%)	0.460
	Female	42 (44.70%)	37 (39.4%)	
Age	≤ 50 Years	21 (22.3%)	23 (24.5%)	0.730
	> 50 Years	73 (77.7%)	71 (75.5%)	
Diabetes	Yes	35 (37.2%)	27 (28.7%)	0.215
	No	59 (62.8%)	67 (71.3%)	
Hypertension	Yes	33 (35.1%)	25 (26.6%)	0.207
	No	61 (64.9%)	69 (73.4%)	
Smoking status	Yes	26 (27.7%)	30 (31.9%)	0.524
	No	68 (72.3%)	64 (68.1%)	
Obesity	Yes	39 (41.5%)	35 (37.2%)	0.550
	No	55 (58.5%)	59 (62.8%)	
Hyperlipidemia	Yes	35 (37.2%)	36 (38.3%)	0.880
	No	59 (62.8%)	58 (61.7%)	
Family History of Coronary Disease	Yes	41 (43.6%)	29 (30.9%)	0.070
	No	53 (56.4%)	65 (69.1%)	

Table 2: frequencies and percentages for major adverse cardiovascular event (mace) in both groups

Group	MACE	Frequency	Percent	P Value
DEB (n=94)	Yes	15	16.0%	0.000
	No	79	84.0%	
	Total	94	100.0%	
DES (n=94)	Yes	38	40.4%	
	No	56	59.6%	
	Total	94	100.0%	

DISCUSSION:

Drug-eluting stents (DES) are still considered to be the best option for percutaneous coronary intervention (PCI) since they significantly lower the risk of in-stent restenosis (ISR) when compared to bare metal stents (BMS) ^{9, 10}. Regardless of the increasing use of newer generation DES, DES-ISR still manifests in 5–10% of patients following DES deployment ^{11, 12}, and it has now become a prevalent therapeutic problem ^{13, 14}. Additionally, DES-ISR therapy is linked to poorer long-term results when compared to BMS ISR; recent data indicate that 10 to 20% of these individuals will go on to get recurrent ISR after many stentings ^{15, 16}. DEB angioplasty is a novel therapeutic approach for BMS-ISR and DES-ISR; studies have shown that it is linked with better results when compared to other traditional treatment techniques ^{16, 17}. Because it may prevent new metal layers and prolonged dual anti-platelet treatment, DEB is a desirable option for recurrent DES-ISR (DAPT). Recurrent DES-ISR managed with DEB has

only been the subject of a small number of trials, and the outcomes are debatable ¹⁸⁻²⁰.

This study was conducted on 188 patients (94 patients in each group) admitted at the Department of Cardiology, MTI-Hayatnabad Medical Complex, Peshawar. In DEB group, the mean (\pm SD) age, duration of symptoms, BMI was 51.43 (\pm 5.104) years, 3.52 (\pm 1.233) months and 25.39 (\pm 0.88) kg/m² respectively while in DES group, the mean (\pm SD) age, duration of symptoms, BMI was 51.49 (\pm 5.299), 3.56 (\pm 1.205) and 25.364 (\pm 0.885) respectively. Other previous studies carried out by Ferri LA et al. and Wang G et al. reported comparable findings to our study ^{5, 6}.

As per main outcome variable of our study, in DEB group, 15 (16.0%) patients were recorded with MACE. In DES group, 38 (40.4%) patients were recorded with MACE. Previous studies carried out by MJ et al. and Gao L et al. reported almost similar

findings^{7, 8}. In accordance with our study another study carried out by Varghese et al. shows that cardiovascular events were observed in 30.8% while ischemia-driven target lesion revascularization were observed in 24.2% patients of recurrent DES-ISR managed by new-generation DES repeat deployment²¹.

A new strategy for ISR treatment is drug-eluting balloon angioplasty. Outcome of these treatment modalities is not widely known. Similar with our findings, in previous study MACE (major adverse cardiovascular event) was observed in 32.9% patients treated with reimplanted DES and in 17.2% patients treated with DEB⁶. The major limitation of our study was small sample size and single centre nature of the study. It is necessary to conduct a larger prospective, randomized study to evaluate both therapy options for recurrent DES-ISR.

CONCLUSION:

Our study demonstrated that DEB is superior to DES in the in-stent restenosis treatment and a smaller number of major adverse cardiovascular events (MACE) in managing CAD, and therefore DEB may be considered as an alternative choice for treatment of CAD patients admitted in our setting in order to reduce mortality and morbidity associated with restenosis in such patients.

REFERENCES:

1. Cui K-Y, Lyu S-Z, Zhang M, Song X-T, Yuan F, Xu F. Drug-eluting balloon versus new-generation drug-eluting stent for the treatment of in-stent restenosis: an updated systematic review and meta-analysis. *Chin Med J*. 2018;131(05):600-7.
2. Paramasivam G, Devasia T, Jayaram A, Razak A, Rao MS, Vijayvergiya R, et al. In-stent restenosis of drug-eluting stents in patients with diabetes mellitus: Clinical presentation, angiographic features, and outcomes. *Anatolian journal of cardiology*. 2020;23(1):28.
3. Goel SS, Dilip Gajulapalli R, Athappan G, Philip F, Gupta S, Murat Tuzcu E, et al. Management of drug eluting stent in-stent restenosis: A systematic review and meta-analysis. *Catheter Cardiovasc Interv*. 2016;87(6):1080-91.
4. Zheng J-F, Guo T-T, Tian Y, Wang Y, Hu X-Y, Chang Y, et al. Clinical characteristics of early and late drug-eluting stent in-stent restenosis and mid-term prognosis after repeated percutaneous coronary intervention. *Chin Med J*. 2020;133(22):2674-81.
5. Ferri LA, Jabbour RJ, Giannini F, Benincasa S, Ancona M, Regazzoli D, et al. Safety and

efficacy of rotational atherectomy for the treatment of undilatable underexpanded stents implanted in calcific lesions. *Catheter Cardiovasc Interv*. 2017;90(2):E19-E24.

6. Wang G, Zhao Q, Chen Q, Zhang X, Tian L, Zhang X. Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis. *Coron Artery Dis*. 2019;30(7):473.
7. Varghese MJ, Bhatheja S, Baber U, Kezbor S, Chincholi A, Chamaria S, et al. Intravascular brachytherapy for the management of repeated multimetall-layered drug-eluting coronary stent restenosis. *Circ Cardiovasc Interv*. 2018;11(10):e006832.
8. Gao L, Wang Y-B, Jing J, Zhang M, Chen Y-D. Drug-eluting balloons versus new generation drug-eluting stents for the management of in-stent restenosis: an updated meta-analysis of randomized studies. *Journal of Geriatric Cardiology: JGC*. 2019;16(6):448.
9. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. *N Engl J Med*. 2003;349(14):1315-23.
10. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. *N Engl J Med*. 2004;350(3):221-31.
11. Kedhi E, Joesoef KS, McFadden E, Wassing J, Van Mieghem C, Goedhart D, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. *The Lancet*. 2010;375(9710):201-9.
12. Harjai KJ, Kondareddy S, Pinkosky B, Harjai N, Orshaw P, Boura J. Everolimus-Eluting Stents Versus Sirolimus-or Paclitaxel-Eluting Stents: Two-Year Results from the Guthrie Health Off-Label Stent (GHOST) Registry. *J Interv Cardiol*. 2013;26(2):153-62.
13. Alfonso F, Byrne RA, Rivero F, Kastrati A. Current treatment of in-stent restenosis. *J Am Coll Cardiol*. 2014;63(24):2659-73.
14. Theodoropoulos K, Mennuni MG, Dangas GD, Meelu OA, Bansilal S, Baber U, et al. Resistant in-stent restenosis in the drug eluting stent era. *Catheter Cardiovasc Interv*. 2016;88(5):777-85.
15. Marquis-Gravel G, Matteau A, Potter BJ, Gobeil F, Noiseux N, Stevens L-M, et al. Impact of Paclitaxel-Eluting Balloons Compared to Second-Generation Drug-Eluting Stents for of In-Stent Restenosis in a Primarily Acute

- Coronary Syndrome Population. *Arq Bras Cardiol.* 2017;109:277-83.
16. Siontis GC, Stefanini GG, Mavridis D, Siontis KC, Alfonso F, Pérez-Vizcayno MJ, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. *The Lancet.* 2015;386(9994):655-64.
 17. Alfonso F, Scheller B. Management of recurrent in-stent restenosis: onion skin full metal jacket? *EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.* 2013;9(7):781-5.
 18. Alfonso F, García J, Pérez-Vizcayno M-J, Hernando L, Hernandez R, Escaned J, et al. New stent implantation for recurrences after stenting for in-stent restenosis: implications of a third metal layer in human coronary arteries. *J Am Coll Cardiol.* 2009;54(11):1036-8.
 19. Kubo S, Kadota K, Otsuru S, Hasegawa D, Shigemoto Y, Habara S, et al. Optimal treatment of recurrent restenosis lesions after drug-eluting stent implantation for in-stent restenosis lesions. *Eurointervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.* 2013;9(7):788-96.
 20. Kawamoto H, Ruparelia N, Latib A, Miyazaki T, Sato K, Mangieri A, et al. Drug-coated balloons versus second-generation drug-eluting stents for the management of recurrent multimetall-layered in-stent restenosis. *JACC Cardiovasc Interv.* 2015;8(12):1586-94.
 21. Auer J, Stone GW. Routine angiographic surveillance for risk stratification in PCI-treated patients: fact or fiction? : Oxford University Press; 2015. p. 71-4.